MAPT and Alzheimer disease: Tau-targeting antisense oligonucleotides, NIO752 and BIIB080, that inhibit translation of tau mRNA into the tau protein, and drugs designed to inhibit tau aggregation/self-association LY3372689, TRx0237 and OLX-07010 are also in clinical trial as is nicotinamide riboside, which has been shown to decrease tau phosphorylation (Hou et al., 2018), attenuate cognitive deterioration and improve synaptic plasticity in mouse models of AD (Gong et al., 2013; Hou et al., 2018).